Covered recipient · General Payments record
JASON C CHANDLER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$56,928.77
103 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,288.00 | 11 |
| Consulting Fee | $15,160.60 | 5 |
| Travel and Lodging | $4,297.87 | 7 |
| Food and Beverage | $3,182.30 | 80 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $19,607.14 | 15 |
| BeOne Medicines USA, Inc. | $18,912.14 | 11 |
| Kite Pharma, Inc. | $10,901.35 | 17 |
| Genentech USA, Inc. | $3,055.05 | 5 |
| Janssen Biotech, Inc. | $1,465.38 | 4 |
| E.R. Squibb & Sons, L.L.C. | $929.65 | 3 |
| Janssen Scientific Affairs, LLC | $840.00 | 1 |
| Celgene Corporation | $238.21 | 7 |
| ADC THERAPEUTICS AMERICA, INC. | $135.40 | 2 |
| SOBI, INC | $94.49 | 4 |
| Daiichi Sankyo Inc. | $93.69 | 5 |
| Incyte Corporation | $73.48 | 3 |
| PFIZER INC. | $62.72 | 3 |
| GlaxoSmithKline, LLC. | $61.61 | 3 |
| Karyopharm Therapeutics Inc. | $55.67 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $49.41 | 2 |
| KYOWA KIRIN, INC. | $47.27 | 2 |
| Syndax Pharmaceuticals, Inc. | $41.29 | 2 |
| Novartis Pharmaceuticals Corporation | $40.03 | 2 |
| Legend Biotech USA Inc. | $33.52 | 1 |
| ABBVIE INC. | $32.77 | 2 |
| BeiGene USA, Inc. | $31.88 | 1 |
| Lilly USA, LLC | $30.25 | 1 |
| Astellas Pharma US Inc | $27.49 | 1 |
| SERVIER PHARMACEUTICALS LLC | $18.12 | 1 |
| Pharmacosmos Therapeutics Inc. | $17.84 | 1 |
| Acrotech Biopharma Inc. | $17.59 | 1 |
| AstraZeneca Pharmaceuticals LP | $15.33 | 1 |
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JASON C CHANDLER
NPI 1295778330 · CMS profile ID 104698
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
GERMANTOWN, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- JASON C CHANDLER, NPI 1295778330, CMS profile ID 104698, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1295778330?year=2025&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
103 matching records · $56,928.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–103 of 103.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| SOBI, INC | $21.34 | 01/14/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1240242688 | CMS |
| Daiichi Sankyo Inc. | $16.50 | 01/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1197075957 | CMS |
| Genentech USA, Inc. | $16.74 | 01/07/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211521447 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $634,772.37 | 49 |
| PY2024 | Recipient | $989.11 | 4 |
| PY2024 | Principal investigator | $237,912.77 | 30 |
| PY2023 | Principal investigator | $264,761.17 | 24 |
| PY2022 | Principal investigator | $52,703.93 | 14 |
| PY2021 | Principal investigator | $19,888.86 | 6 |
| PY2020 | Principal investigator | $71,993.00 | 15 |
| PY2019 | Principal investigator | $62,122.32 | 25 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
49 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $144.00 | 12/31/2025 | Non-covered Recipient Entity WEST CLINIC PC | A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting | No dispute reported | 06/30/2026 | 1202533765 |
| Principal investigator 1 | ABBVIE INC. | $2,640.60 | 12/23/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202531834 |
| Principal investigator 1 | ABBVIE INC. | $6,847.20 | 12/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202529028 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 11/26/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202525498 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,381.00 | 11/26/2025 | Non-covered Recipient Entity The West Clinic, Pllc Dba West Cancer Center | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1235992949 |
| Principal investigator 1 | Incyte Corporation | $5,660.53 | 11/25/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240618438 |
| Principal investigator 1 | Incyte Corporation | $6,976.16 | 11/10/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240618442 |
| Principal investigator 1 | ABBVIE INC. | $7,059.15 | 11/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202521977 |
| Principal investigator 1 | Genentech, Inc. | $8,231.00 | 11/05/2025 | Non-covered Recipient Entity The West Clinic PLLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211671780 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $64,033.00 | 11/03/2025 | Non-covered Recipient Entity The West Clinic, Pllc Dba West Cancer Center | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235992951 |
| Principal investigator 1 | Genentech, Inc. | $5,569.00 | 10/20/2025 | Non-covered Recipient Entity The West Clinic PLLC | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211671778 |
| Principal investigator 1 | ABBVIE INC. | $8,819.55 | 10/09/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202515425 |
| Principal investigator 1 | ABBVIE INC. | $16,538.94 | 09/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202511336 |
| Principal investigator 1 | ABBVIE INC. | $2,090.00 | 09/18/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202511350 |
| Principal investigator 1 | ABBVIE INC. | $1,023.00 | 09/17/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202511138 |
| Principal investigator 1 | ABBVIE INC. | $24,389.10 | 09/04/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202508606 |
| Principal investigator 1 | ABBVIE INC. | $1,557.00 | 08/21/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202505455 |
| Principal investigator 1 | Genentech, Inc. | $6,678.00 | 08/08/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684892 |
| Principal investigator 1 | ABBVIE INC. | $3,792.15 | 08/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202503051 |
| Principal investigator 1 | Genentech, Inc. | $6,583.00 | 07/29/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684888 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 07/24/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202499548 |
| Principal investigator 1 | ABBVIE INC. | $375.30 | 07/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202498234 |
| Principal investigator 1 | Genentech, Inc. | $2,757.00 | 07/07/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684890 |
| Principal investigator 1 | ABBVIE INC. | $19,423.80 | 07/02/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202494983 |
| Principal investigator 1 | ABBVIE INC. | $596.00 | 06/13/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202491407 |
| Principal investigator 1 | Genentech, Inc. | $6,433.00 | 05/28/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684878 |
| Principal investigator 1 | Genentech, Inc. | $18,294.00 | 05/14/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684882 |
| Principal investigator 1 | ABBVIE INC. | $2,371.82 | 05/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202482049 |
| Principal investigator 1 | ABBVIE INC. | $792.00 | 05/01/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202480831 |
| Principal investigator 1 | Genentech, Inc. | $6,855.00 | 04/29/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684880 |
| Principal investigator 1 | Celgene Corporation | $35,283.00 | 04/28/2025 | Non-covered Recipient Entity Margaret West Comprehensive Breast Center | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1222305312 |
| Principal investigator 1 | Eli Lilly and Company | $23,755.00 | 04/28/2025 | Non-covered Recipient Entity THE WEST CLINIC | A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR | No dispute reported | 06/30/2026 | 1187892538 |
| Principal investigator 1 | ABBVIE INC. | $2,764.00 | 04/15/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202476564 |
| Principal investigator 1 | Incyte Corporation | $5,762.90 | 04/15/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240618434 |
| Principal investigator 1 | ABBVIE INC. | $12,036.00 | 04/03/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | Study Assessing Activity of Intravenous (IV) ABBV-383 Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | No dispute reported | 06/30/2026 | 1202473172 |
| Principal investigator 1 | ABBVIE INC. | $2,371.82 | 04/03/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202473175 |
| Principal investigator 1 | ABBVIE INC. | $792.00 | 04/03/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202473180 |
| Principal investigator 1 | Genentech, Inc. | $13,000.00 | 04/01/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684884 |
| Principal investigator 1 | Genentech, Inc. | $3,544.00 | 04/01/2025 | Non-covered Recipient Entity WEST CLINIC PC RESEARCH ACCOUNTING | Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL | No dispute reported | 06/30/2026 | 1211684886 |
| Principal investigator 1 | ABBVIE INC. | $2,371.82 | 03/06/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202457902 |
| Principal investigator 1 | ABBVIE INC. | $1,175.00 | 02/27/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202454323 |
| Principal investigator 1 | Incyte Corporation | $1,000.00 | 02/25/2025 | Non-covered Recipient Entity WEST CANCER CENTER AND RESEARCH INSTITUTE | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind | No dispute reported | 06/30/2026 | 1240618430 |
| Principal investigator 1 | Eli Lilly and Company | $1,627.05 | 02/10/2025 | Non-covered Recipient Entity THE WEST CLINIC | A PHASE 2, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF 3 DOSES OF PIRTOBRUTINIB IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA WHO PREVIOUSLY RECEIVED TREATMENT WITH A COVALENT BRUTON TYROSINE KINASE INHIBITOR | No dispute reported | 06/30/2026 | 1187893186 |
| Principal investigator 1 | ABBVIE INC. | $2,371.82 | 02/05/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202444366 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $6,463.91 | 01/27/2025 | Non-covered Recipient Entity West Cancer Center | A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (Excaliber-Maintenance) | No dispute reported | 06/30/2026 | 1235991710 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,954.93 | 01/27/2025 | Non-covered Recipient Entity The West Clinic, Pllc Dba West Cancer Center | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1235992947 |
| Principal investigator 1 | ABBVIE INC. | $588.00 | 01/14/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202438298 |
| Principal investigator 1 | Celgene Corporation | $267,329.00 | 01/10/2025 | Non-covered Recipient Entity Margaret West Comprehensive Breast Center | A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING MEZIGDOMIDE (CC-92480), BORTEZOMIB AND DEXAMETHASONE (MEZIVd) VERSUS POMALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE (PVd) IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-1 | No dispute reported | 06/30/2026 | 1222305272 |
| Principal investigator 1 | ABBVIE INC. | $2,371.82 | 01/02/2025 | Non-covered Recipient Entity THE WEST CLINIC PLLC | M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 1202434039 |